Summary of Conference Call for Shanmei International Company Overview - **Company**: Shanmei International - **Industry**: Coal Mining and Trading Key Points Financial Performance and Projections - The company expects a concentration of expenses in Q4, with no new capital replacement indicator expenditures, as the last batch of indicators has been purchased [2][5] - The average selling price in Q4 shows an upward trend as of October, although complete data is not yet available [3] - The cost target for 2025 is approximately ten yuan lower than the previous year, with some expenses expected to be concentrated in Q4 [4] Production and Sales - The import trade coal business is expected to see a significant decline in advantages by 2026, with projections indicating that 2027 will not reach the 10 million tons level of 2024 [2][6] - The long-term contract coal volume for 2026 is set at 20 million tons, a decrease of 1 million tons from 2025, with stable production targets around 35 million tons [2][10] - The company maintains a balanced production of thermal coal and coking coal, targeting 35 million tons, while managing inventory levels to align with last year's figures [8][9] Taxation and Regulatory Environment - Resource tax remains stable between 9.5-10, with no fixed downward trend anticipated, although some special inspections may occur [7] - The company has purchased all necessary capacity indicators, ensuring no risk of overproduction, even with strict policy enforcement [15] Shareholder Returns and Capital Expenditure - The company aims to maintain a 60% dividend payout ratio while balancing resource expansion and shareholder returns, with plans for 2027-2029 yet to be defined [2][12] - Capital expenditures for 2027 are expected to remain within the normal maintenance range of 1.2 to 1.5 billion yuan [14] Market Dynamics and Pricing Strategies - The pricing mechanism for long-term contracts in 2026 will utilize both pithead and port pricing, with adjustments based on market conditions [9] - The company has successfully negotiated coal prices with power plants, which have been adjusted monthly since May [17] Operational Challenges - Winter snowfall may have short-term impacts on production, particularly in transportation, but overall operations in Shanxi are expected to remain stable [18] Strategic Planning - The company is actively seeking resources in Shaanxi, with an investment return rate set at the state-owned enterprise standard of 8% [14] - There are no immediate plans for new pledges from the controlling shareholder, as previous debts have been settled [16] Additional Insights - The metallurgical coal products are primarily sold based on market demand without long-term pricing agreements, indicating a flexible sales strategy [11] - The company is focused on smart mining upgrades, although specific expenditure details are not yet available, with benefits expected to materialize over time [13]

证券代码：688229 证券简称：博睿数据 公告编号：2026-007 二、上年同期业绩情况 北京博睿宏远数据科技股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日 （二）业绩预告情况 1、经北京博睿宏远数据科技股份有限公司（以下简称"公司"）财务部门初步测算，预计公司2025年年 度营业收入为12,500.00万元到13,500.00万元，与上年同期相比，将减少555.61万元到1,555.61万元，同 比减少3.95%到11.07%。 2、预计公司2025年年度实现归属于母公司所有者的净利润为-9,000.00万元到-10,000.00万元，与上年同 期相比，将增加1,517.45万元到2,517.45万元。 3、预计公司2025年年度归属于母公司所有者的扣除非经常性损益的净利润为-9,100.00万元到-10,100.00 万元，与上年同期相比，将增加1,571.15万元到2,571.15万元。 4、 ...

Core Viewpoint - Northeast Pharmaceutical is actively pursuing a strong start to Q1 2026 by focusing on production capacity, market expansion, and collaborative efforts across all departments to ensure high-quality operations throughout the year [1]. Group 1: Customer Audits and Production - Customer audits are crucial for product quality and management, serving as a key link to the market and stabilizing partnerships. As of January 14, Northeast Pharmaceutical successfully completed audits for 6 domestic and international clients, involving 4 production plants and 7 raw material products, all passing the reviews [2]. - The production front is identified as the core battlefield for achieving a strong start. Various production plants have mobilized to meet the surge in demand, with innovative strategies such as "modular rapid switching" and continuous operations during holidays to ensure timely delivery of customized orders [2]. Group 2: Data-Driven Sales and Cost Efficiency - The sales team is leveraging data to drive market opportunities, ensuring sufficient inventory for best-selling products and maintaining uninterrupted market supply. This proactive approach aims to expand growth potential for the strong start [3]. - Cost reduction and efficiency enhancement are vital for achieving a strong start. The production command center is implementing refined management practices, focusing on key data changes and organizing weekly meetings to analyze production cost indicators, thereby improving product competitiveness [3]. Group 3: Collaborative Innovation - Subsidiaries are actively contributing to the strong start through innovative approaches and a unified strategy. For instance, the technology service company has signed contracts with multiple clients to expand external markets, while logistics and design companies are enhancing efficiency and project delivery through innovative technologies [4]. - The overall strategy emphasizes collaboration across business lines, aiming for a coordinated effort to achieve the Q1 goals and support high-quality development throughout the year [4].

截至本公告日期，图迈全球范围内累计商业化订单超过180台，累计商业化装机量已突破120台。 董事会预计集团于截至2025年12月31日止年度将取得经调整净亏损不超过人民币2.40亿元，较截至2024 年12月31日止年度的经调整净亏损(约人民币4.82亿元)缩窄超过50%，该亏损缩窄乃主要归功于营业收 入快速增长，以及降本增效多措并举下，产品成本及运营费用的大幅下降。同时，得益于集团高效的现 金流管控措施，集团于截至2025年12月31日止年度自由现金流净流出较截至2024年12月31日止年度大幅 收窄80%以上，至不超过人民币7000万元。 微创机器人-B(02252)发布公告，董事会预期公司截至2025年12月31日止年度的收入较截至2024年12月 31日止年度同比增长约110%至120%。该大幅跃升主要归因于核心产品图迈腔镜手术机器人商业化取得 突破性进展，销售增长迅猛，尤其是图迈海外市场拓展成效显著，全年新签海外市场订单逾百台，全年 海外市场销售收入为去年的五倍以上，增速远超行业平均水平，展现出强劲的全球扩张动能。 ...

Group 1 - The core viewpoint of the article is that the company's profitability is expected to improve in the first three quarters of 2025 due to business structure optimization and effective cost reduction measures [2] - The company has deepened lean management and promoted refined cost control during the reporting period [2] - There has been an increased focus on technological research and innovation, enhancing the level of intelligence and testing efficiency, which has led to a steady increase in gross profit margin [2]

Core Insights - Lingxiong Technology Group Co., Ltd. is the largest enterprise-level DaaS (Device as a Service) provider in China, established in 2004, and has developed a digital, multi-scenario, and closed-loop DaaS business model [1] - The company has been recognized as a national public service demonstration platform for small and medium-sized enterprises and a national-level specialized and innovative "little giant" enterprise [1] Group 1 - Lingxiong Technology focuses on customer needs and has innovated its digital DaaS service model, offering a full-stack service including IT equipment subscription, technical subscription, device management SaaS, and equipment recycling [1] - The company has assisted tens of thousands of enterprises, including many Fortune 500 companies, in addressing IT equipment lifecycle management challenges, thereby promoting cost reduction and digital upgrades [1] Group 2 - From October 2024 to October 2025, Lingxiong Technology will deepen its digital closed-loop DaaS solutions, creating a comprehensive service system that includes "equipment subscription - technical support - management services - recycling and reuse" [2] - The core model of "customized on demand, pay per use" provides flexible and efficient IT infrastructure support for enterprises [2] Group 3 - The solutions have quantifiable effects: compared to traditional procurement models, they can reduce initial investment by 97.4% and lower operational costs by 10% to 30% over three years [3] - The "rent as needed" model allows enterprises to dynamically adjust equipment quantities, alleviating cash flow pressure while avoiding maintenance and disposal costs [3] - Lingxiong Technology has successfully helped numerous SMEs overcome the IT infrastructure barriers to digital transformation [3] Group 4 - The solutions leverage industry-leading remanufacturing technology to extend the lifecycle of millions of IT devices, reducing the demand for new equipment and lowering annual carbon emissions by thousands of tons [3] - In 2024 alone, the company contributed a net carbon reduction of over 83,740 tons to society [3] - Since the 14th Five-Year Plan, Lingxiong Technology has achieved a revenue CAGR of over 20% [3]

本期业绩预亏的主要原因：2025年度，公司所在房地产行业仍处于下行周期，公司装配式空间产品所处 下游市场已进入存量时代，导致公司主营业务收入同比下降。2025年度，公司持续优化战略布局，扎实 推进降本增效工作，亏损幅度较上年显著收窄。 格隆汇1月21日丨法狮龙(605318.SH)公布，公司预计2025年年度实现归属于上市公司股东的净利润 为-600万元至-400万元。公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润 为-995万元至-795万元。 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 17.25 [1][9]. Core Insights - The company is expected to achieve significant profit growth, with a projected net profit for 2025 ranging from RMB 1.58 billion to RMB 1.74 billion, representing a year-on-year increase of 50% to 65% [6]. - The company anticipates a reduction in losses for Q4 2025 compared to Q4 2024, driven by land reserve contributions and operational improvements [6]. - The U8 product line is expected to continue its rapid growth, supported by strategic market expansions and new product launches at a price point of RMB 10 [7][9]. Financial Performance and Forecast - Revenue projections for the company are as follows: RMB 14.67 billion in 2024, RMB 15.14 billion in 2025, RMB 15.48 billion in 2026, and RMB 15.84 billion in 2027, with growth rates of 3.20%, 3.24%, 2.25%, and 2.32% respectively [5]. - The net profit attributable to the parent company is forecasted to be RMB 1.06 billion in 2024, RMB 1.68 billion in 2025, RMB 1.95 billion in 2026, and RMB 2.25 billion in 2027, with growth rates of 63.74%, 59.29%, 16.09%, and 15.12% respectively [5]. - The company’s EPS is projected to increase from RMB 0.37 in 2024 to RMB 0.80 in 2027 [5]. Valuation Metrics - The company’s PE ratio is expected to decrease from 33.40 in 2024 to 15.69 in 2027, indicating an improving valuation as earnings grow [5]. - The target price of RMB 17.25 corresponds to a PE of 25x for 2026, reflecting a higher growth rate compared to peers [9][10]. Market Position and Strategy - The company is focusing on optimizing its product structure and reducing costs, which is expected to enhance profit margins [8]. - The beverage business is anticipated to contribute significantly to revenue growth, particularly in core markets [7]. - The company is also benefiting from trends towards health-conscious products, particularly in its natto business [7].

Core Viewpoint - The company emphasizes a market-oriented pricing strategy and ongoing efforts to reduce costs and improve efficiency across various dimensions [2] Group 1: Pricing Strategy - The company states that its pricing principles are based on market conditions and raw material prices, which are considered in determining product prices [2] Group 2: Cost Management - The company has been actively promoting cost reduction and efficiency enhancement initiatives, focusing on raw material cost management, comprehensive cost control, production yield improvement, and optimization of production processes [2]

Core Viewpoint - Yuheng Pharmaceutical (002437) expects a significant increase in net profit for 2025, projecting a range of CNY 350 million to CNY 420 million, representing a year-on-year growth of 50.37% to 80.44% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of CNY 350 million to CNY 420 million for 2025, compared to CNY 233 million in the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between CNY 185 million and CNY 220 million, reflecting a growth of 0.92% to 20.02% from CNY 183 million in the previous year [1] Group 2: Product Development and Market Position - Yuheng Pharmaceutical focuses on the research, production, and sales of pharmaceuticals, with a strong emphasis on high-barrier generic drugs, including pre-filled methotrexate injection [1] - The company has over 300 drug registration certificates, covering various therapeutic areas such as musculoskeletal, cardiovascular, vitamins and minerals, diabetes, analgesics, anti-infection, and anti-tumor [1] - Key products like multi-vitamin injections, potassium chloride sustained-release tablets, and others have maintained high market shares in their respective segments [2] Group 3: Sales and Marketing Strategy - The company primarily sells prescription drugs through hospitals, with some products available in retail pharmacies and e-commerce platforms [2] - Yuheng Pharmaceutical employs a refined招商 (investment promotion) and specialized academic promotion strategy for sales [2] - The company has a low export business proportion, currently limited to sodium phosphate injection to Uzbekistan, with future plans to expand exports in line with the Belt and Road Initiative [2] Group 4: Operational Efficiency - The company has achieved notable results in cost reduction and efficiency improvement, with decreases in both sales and management expenses compared to the same period in 2024 [3] - A non-recurring gain of CNY 132 million from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd. is expected to be included in the 2025 investment income [3]